Anti-Human CCR7 Reference Antibody (CAP-100, RUO) (HB053026)

Name: Anti-Human CCR7 Reference Antibody (CAP-100, RUO)
Brand: abinScience
SKU: HB053026
Price: 176 USD
Availability: InStock

データシート製品共有情報コピー

価格(USD):

スペック:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート
SDS

概要

カタログ番号	HB053026
種反応性	Human
アプリケーション	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種	Human
クローン性	Monoclonal
アイソタイプ	IgG
クローンID	CAP-100
生物学的活性	CAP-100 (0.1-10 ng/uL) demonstrates the most potent binding to CCR7 immunogen SYM1899 (100 ng) with a EC 50 of 1.78 ng/mL [1]. CAP-100 (0.01-100 ug/mL) shows dose-dependent inhibition of ligand-induced activation, reaching maximal inhibitions close to 100% in CCR7 + CHO-K1 cells stimulated with CCL19 [1]. CAP-100 (0.1-100 ug/mL) binds to CCR7 + non-tumor PB or BM cells from healthy donors at high experimental concentrations [1]. CAP-100 (1-100 ug/mL) impairs the increase of D-actin upon CCL19/CCL21 stimulation in CLL cells [1]. CAP-100 (0.1-100 ug/mL, 4 h) demonstrates a strong dose-related inhibitory activity against CCR7-driven T-PLL cells migration towards 1 ug/mL of CCL19 or CCL21 [1]. CAP-100 (10 ug/mL) impairs CCR7-induced migration of CCL cells in trans-endothelial migration (TEM) assays [1]. CAP-100 (10-100 ug/mL, 24 h) does not mediate direct specific-induced cell death but impairs the viability of CCR7-mediated cells which is the protective function in CLL [1]. CAP-100 (10 ug/mL) activated human NK-92-CD16 + cells to induce a strong ADCC on target CLL cells [1]. CAP-100 (10 ug/mL, i.v., one single dose) reduces in vivo homing of CCR7-expressing cells to lymph node of NSG mice [1]. CAP-100 (25-200 ug/mouse, i.v., one single dose) shows prolonged median overall survival regardless of dose and reduces tumor burden as well as reducing lymph node infiltration in Granta-519-luc + -bearing mice [1]. CAP-100 (10-200 ug/mouse, i.v., one single dose) significantly extends the lifespan of JVM-3-bearing SCID mice compared to Trastuzumab () (200 ug) [1].
発現システム	Mammalian cells
ターゲット	CDw197, EVI1, CMKBR7, CCR7, C-C CKR-7, CD197, CCR-7, Epstein-Barr virus-induced G-protein coupled receptor 1, MIP-3 beta receptor, EBI1, CC-CKR-7, BLR2, EBV-induced G-protein coupled receptor 1, C-C chemokine receptor type 7
エンドトキシンレベル	< 10 EU/mg
純度	>95% purity as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	P32248
形態	Liquid
保存バッファー	0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名	CAP-100, CAP100, CAP100
背景	C-C chemokine receptor type 7 (CD197/CCR7) is a ~42 kDa protein. Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions.
参考文献	1. Cuesta-Mateos C, et al., Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs. 2021 Jan-Dec;13(1):1917484. [HB053026]
注意事項	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107)

イメージ

Bioactivity

SEC-HPLC detection for Research Grade Anti-Human CD197/CCR7 (CAP-100).
SDS-PAGE

SDS-PAGE for Research Grade Anti-Human CD197/CCR7 (CAP-100).